Compare Eaton Corporation plc (ETN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eaton Corporation plc vs Merck & Co., Inc. — how do they compare? Eaton Corporation plc trades at $430.45 (market cap $164.88B), while Merck & Co., Inc. trades at $146.23 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 2.1× Eaton Corporation plc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eaton Corporation plc for 31 Days and Merck & Co., Inc. for 98 Days on average.
| ETN | MRK | |
|---|---|---|
Market Cap | $164.88B | $351.28B |
Volume | 2,535,086 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $459.96 | $156.43 |
52-Week Low | $315.82 | $82.49 |
Typical Hold Time | 31 Days | 98 Days |
Enterprise Value | $185.51B | $398.04B |
Dividend Yield | 1.04% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eaton Corporation (ETN) trades at $430.25, down 0.25% with bearish technical signals but strong fundamentals. The company has beaten earnings estimates for three consecutive quarters, maintains healthy margins (12.75% net income), and benefits from strategic acquisitions in data center and aerospace markets. Analyst consensus remains strongly bullish with a $502.38 price target, though technical indicators show near-term pressure with support at $418.
ETN presents a compelling growth story driven by AI data center demand and grid modernization trends, but faces execution risks from recent acquisitions and competitive pressure from peers like Vertiv. The stock's premium valuation (P/E 43.23) requires sustained earnings growth to justify, making upcoming Q3 earnings on November 5 critical for momentum.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
